Alert over JAK inhibitor’s blood clot risk
The TGA says patients on high doses of tofacitinib need to be warned
Patients on the Janus kinase inhibitor tofacitinib should be monitored, and warned about signs and symptoms of pulmonary embolism, the TGA says.
The product information has been updated to include details from an ongoing safety study that linked high doses (10mg twice daily) to increased risk of blood clots and death.
